Compound: N-(3,5-Dimethyl-4-isoxazolylmethyl)phthalimide
SMILES: O=C1N(C(=O)c2c1cccc2)Cc3c(onc3C)C
InChIKey: SHPRUADECKZSMQ-UHFFFAOYSA-N
Synonyms: N-(3,5-Dimethyl-4-isoxazolylmethyl)phthalimide, 39962-28-2, BW49C59ULP, DTXSID40193001, 2-((3,5-Dimethyl-4-isoxazolyl)methyl)-1H-isoindole-1,3(2H)-dione, 1h-isoindole-1,3(2h)-dione, 2-[(3,5-dimethyl-4-isoxazolyl)methyl]-, Ro7-8117, 1H-Isoindole-1,3(2H)-dione, 2-((3,5-dimethyl-4-isoxazolyl)methyl)-, 2-[(3,5-Dimethyl-4-isoxazolyl)methyl]-1H-isoindole-1,3(2H)-dione, RefChem:161848, DTXCID10115492, 2-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]isoindole-1,3-dione, 2-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-1H-isoindole-1,3(2H)-dione, Ro 7-8117, MLS001150179, N-3,5-Dimethyl-4-isoxazolyl-methyl phthalimide, UNII-BW49C59ULP, Phthalimide, N-(3,5-dimethyl-4-isoxazolylmethyl)-, SCHEMBL2204904, CHEMBL1710671, SHPRUADECKZSMQ-UHFFFAOYSA-N, HMS2978I17, STL219876, AKOS001137040, 2-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-2,3-dihydro-1H-isoindole-1,3-dione, NCGC00247655-01, SMR000688699, Z18271423, 2-(3,5-Dimethyl-isoxazol-4-ylmethyl)-isoindole-1,3-dione
Theoretical properties:
molecular_formula: C14H12N2O3
molecular_weight: 256.26 g/mol
exact_mass: 256.08479225 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 2
heavy_atom_count: 19
topological_polar_surface_area: 63.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: 30.1 [ug/mL] (The mean of the results at pH 7.4)
Descriptions:
{"pubchem": null, "chebi": null, "chembl": "Unnamed Compound is a small molecule listed in the ChEMBL database but has not progressed to an approved clinical phase.", "wikipedia": "Antiandrogens, also known as androgen antagonists or testosterone blockers, are a class of drugs that prevent androgens like testosterone and dihydrotestosterone (DHT) from mediating their biological effects in the body. They act by blocking the androgen receptor (AR) and/or inhibiting or suppressing androgen production. They can be thought of as the functional opposites of AR agonists, for instance androgens and anabolic steroids (AAS) like testosterone, DHT, and nandrolone and selective androgen receptor modulators (SARMs) like enobosarm. Antiandrogens are one of three types of sex hormone antagonists, the others being antiestrogens and antiprogestogens.\nAntiandrogens are used to treat an assortment of androgen-dependent conditions. In men, antiandrogens are used in the treatment of prostate cancer, enlarged prostate, scalp hair loss, overly high sex drive, unusual and problematic sexual urges, and early puberty. In women, antiandrogens are used to treat acne, seborrhea, excessive hair growth, scalp hair loss, and high androgen levels, such as those that occur in polycystic ovary syndrome (PCOS). Antiandrogens are also used as a component of feminizing hormone therapy for transgender women and as puberty blockers in transgender girls.\nSide effects of antiandrogens depend on the type of antiandrogen and the specific antiandrogen in question. In any case, common side effects of antiandrogens in men include breast tenderness, breast enlargement, feminization, hot flashes, sexual dysfunction, infertility, and osteoporosis. In women, antiandrogens are much better tolerated, and antiandrogens that work only by directly blocking androgens are associated with minimal side effects. However, because estrogens are made from androgens in the body, antiandrogens that suppress androgen production can cause low estrogen levels and associated symptoms like hot flashes, menstrual irregularities, and osteoporosis in premenopausal women.\nThere are a few different major types of antiandrogens. These include AR antagonists, androgen synthesis inhibitors, and antigonadotropins. AR antagonists work by directly blocking the effects of androgens, while androgen synthesis inhibitors and antigonadotropins work by lowering androgen levels. AR antagonists can be further divided into steroidal antiandrogens and nonsteroidal antiandrogens; androgen synthesis inhibitors can be further divided mostly into CYP17A1 inhibitors and 5\u03b1-reductase inhibitors; and antigonadotropins can be further divided into gonadotropin-releasing hormone modulators (GnRH modulators), progestogens, and estrogens."}